Session » Antiphospholipid Syndrome Poster

Date: Sunday, November 5, 2017

Time: 9:00AM-11:00AM

Meeting: 2017 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 14

Abnormalities in Th1, Th2 and Th17 Lymphoid Subpopulations in Long-Term Evolution Primary Antiphospholipid Syndrome

9:00AM-11:00AM: Abstract Number: 1

Anti-Phosphatidylserine/Prothrombin Antibodies (aPS/PT) As Potential Diagnostic Markers and Risk Predictors of Venous Thrombosis and Obstetric Complications in Antiphospholipid Syndrome

9:00AM-11:00AM: Abstract Number: 16

Anti-Phosphatidylserine/Prothrombin Antibodies in Primary Antiphospholipid Syndrome

9:00AM-11:00AM: Abstract Number: 12

Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository Analysis: Pregnancy Outcomes Since Inception

9:00AM-11:00AM: Abstract Number: 8

Antiphospholipid Syndrome Leukocytes Demonstrate Increased Adhesive Potential: a Search for Novel Therapeutic Targets

9:00AM-11:00AM: Abstract Number: 10

Arterial Events in Primary Antiphospholipid Syndrome Are Associated with High Values of the Adjusted Global Antiphospholipid Syndrome Score

9:00AM-11:00AM: Abstract Number: 3

Burden of Antiphospholipid Syndrome in a Thromboembolic Disease Registry

9:00AM-11:00AM: Abstract Number: 5

Clinical Utility of the Global Antiphospholipid Syndrome Score (GAPSS) for Risk Stratification: A Pooled Analysisfrom 2273 Patients

9:00AM-11:00AM: Abstract Number: 4

Downregulation of microRNAs in Plasmacytoid Dendritic Cells Is Associated with a Type I Interferon Signature in Systemic Lupus Erythematosus and Antiphospholipid Syndrome

9:00AM-11:00AM: Abstract Number: 13

Epidemiology of Antiphospholipid Syndrome: A Population-Based Study

9:00AM-11:00AM: Abstract Number: 2

Identifying “Second Hit” Risk Factor(s) Associated with Thrombosis and Pregnancy Morbidity in Ethnically Diverse Antiphospholipid Antibodies Positive Patients

9:00AM-11:00AM: Abstract Number: 18

Increased Frequency of Nailfold Videocapillaroscopy Abnormalities in Primaryantiphospolipid (PAPS) Patients

9:00AM-11:00AM: Abstract Number: 15

Methodology and Systematic Review of the Literature for the Mcmaster RARE-Best Practice Clinical Practice Guideline on Diagnosis and Management of the Catastrophic Antiphospholipid Syndrome

9:00AM-11:00AM: Abstract Number: 11

Possible Therapeutics for Antiphospholipid Antibody Related Thrombocytopenia: A Systemic Review and Meta-Analysis

9:00AM-11:00AM: Abstract Number: 7

Predictive Value for Thrombosis of Double or Triple Positivity in Secondary APS Depends on the Component Assays and the Type of Thrombosis

9:00AM-11:00AM: Abstract Number: 6

Pregnancy Outcomes in a Cohort of Women with Antiphospholipid Syndrome. 25- Years Long-Term Observation

9:00AM-11:00AM: Abstract Number: 9

Renal Protective Effect of Antiplatelet Therapy in Antiphospholipid Antibody-Positive Lupus Nephritis Patients without the Antiphospholipid Syndrome

9:00AM-11:00AM: Abstract Number: 17

Thrombotic Events in Pediatric Systemic Lupus Erythematosus: A Preliminary Analysis of a Large, Single-Center Cohort

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].